Enlivex Therapeutics Ltd. has announced the issuance of an Israeli patent, numbered 290470, for its innovative treatment approach using Allocetra for osteoarthritis. This patent, titled THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS, extends Enlivex’s intellectual property protection in Israel until at least 2040, specifically covering methods of utilizing Allocetra in affected patients.
Recent clinical data from the Phase 2a trial of ENX-CL-05-001 underscores the potential of Allocetra, revealing statistically significant improvements in knee pain and function among participants with moderate-to-severe knee osteoarthritis. In the modified intention-to-treat population, Allocetra treatment led to a 24% reduction in knee pain and a 26% enhancement in knee function compared to placebo, with even more pronounced results in age-related primary osteoarthritis patients.
Dr. Oren Hershkovitz, CEO of Enlivex, expressed optimism regarding the patent issuance, indicating it bolsters their confidence in securing similar protections globally. With osteoarthritis affecting over 32.5 million Americans and no FDA or EMA-approved treatments to halt its progression, the need for effective therapies is critical. Enlivex’s focus on macrophage reprogramming through Allocetra positions it as a potential leader in addressing this significant healthcare challenge.
